Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This study uses a randomized, double-blind, controlled design to demonstrate that PN400
(esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal
ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric
ulcers compared to naproxen alone.